

# Structural and functional roles of exosomal nanovesicles in the formation, release and synaptotoxicity of amyloid proteins

<https://neurodegenerationresearch.eu/survey/structural-and-functional-roles-of-exosomal-nanovesicles-in-the-formation-release-and-synaptotoxicity-of-amyloid-proteins/>

## Principal Investigators

Rajendran Lawrence

## Institution

University of Zurich

## Contact information of lead PI Country

Switzerland

## Title of project or programme

Structural and functional roles of exosomal nanovesicles in the formation, release and synaptotoxicity of amyloid proteins

## Source of funding information

SNSF

## Total sum awarded (Euro)

€ 183,486

## Start date of award

01/04/2014

## Total duration of award in years

2

## Keywords

### Research Abstract

Alzheimer's disease (AD), the most common neurodegenerative disease, is a serious threat to the autonomy, mobility, and overall functionality of aging persons worldwide. Although the etiology of AD remains incompletely defined, over a decade of investigation increasingly implicates oligomers of the amyloid- $\beta$  ( $A\beta$ ) peptide as the primary toxic molecular species responsible for the disease. Several studies support a robust correlation between  $A\beta$  oligomer

concentration and the extent of synaptic loss and severity of cognitive impairment, and A $\beta$  oligomers also trigger abnormalities of the microtubule-associated protein tau, which is associated with irreversible neuronal damage. The revised amyloid cascade hypothesis stipulates that when A $\beta$  is generated, by  $\beta$  and  $\gamma$ -secretase cleavage of amyloid precursor protein (APP), the non-toxic A $\beta$  monomers rapidly form soluble, toxic A $\beta$  oligomers, which are then converted to relatively non-toxic insoluble A $\beta$  fibril plaques that are deposited extracellularly. However, much is unknown about the “strain” of A $\beta$  (oligomers, fibrils, post-translationally modified forms) that is toxic and also the subcellular location, cellular basis of A $\beta$  oligomerization and the mechanism of A $\beta$  release from cells remains largely unknown. These mechanisms may also explain the characteristic spreading of A $\beta$  pathology throughout the brain, and could lead to new therapeutic approaches. Recently we showed that exosomes, endocytically derived nanovesicles, carry A $\beta$  peptides out of the cell and to contain the enzymatic machinery required to generate these peptides from APP (1). This suggests that A $\beta$ -associated with lipidic vesicles could confer toxicity as well be seeds for amyloid formation. The overarching goal of this proposal it to demonstrate that exosomes are a major way to shuttle amyloids out of the cell, and that exosome-associated amyloids contribute to AD pathology by enhancing formation of A $\beta$  aggregates.

By combining chemical biology tools, biophysical and structural biology, cell biology and neuroscience, we propose to explore the role of the exosomal nanovesicles in the formation of amyloid aggregates, making it a truly interdisciplinary project.

The subcellular mechanisms governing exosomal-A $\beta$  biogenesis and secretion will be addressed using immunofluorescence and electron microscopy in concert with a novel fluorescently labeled  $\gamma$ -secretase inhibitor. The proteins involved in exosomal release will be investigated using an RNAi silencing screen and the application of various knock out cell lines. The role of exosomes in nucleating amyloid aggregation will be monitored using in vitro aggregation assays and the pathological consequences of exosomal-A $\beta$  will be examined in vivo by assaying plaque propagation after intracerebral injection of exosomal-A $\beta$  in AD mouse models, and by examining tau phosphorylation and synaptic functionality after exosomal-A $\beta$  treatment. The expected results will clarify the role of exosomes in amyloid pathology propagation and define the rules for exosomal-A $\beta$  biogenesis and release from neurons.

**Further information available at:**

**Types:**

Investments < €500k

**Member States:**

Switzerland

**Diseases:**

N/A

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A